Novartis Gene Therapies
Novartis Gene Therapies's Overview
Novartis Gene Therapies, formerly AveXis, is an integral part of Novartis focused on developing and commercializing novel gene therapies for patients suffering from debilitating rare neurological genetic diseases. Their pioneering work includes Zolgensma®, a one-time treatment for spinal muscular atrophy (SMA). Novartis Gene Therapies leverages cutting-edge AAV-based technology and has significant manufacturing and research capabilities. In late 2023, Novartis announced the further integration of its gene therapy operations into its broader global BioPharma organization to enhance innovation, development, and delivery of these transformative treatments. While it operates as a key component of Novartis, its origins and specialized focus on gene replacement and AAV technologies remain central to its mission.
Where is Novartis Gene Therapies's Headquarters?
HQ Function
Key operational hub for gene therapy research, process development, and strategic operations within Novartis.
Notable Features:
Advanced laboratories and facilities dedicated to AAV-based gene therapy research and development, supporting a pipeline of potential treatments.
Work Culture:
As part of Novartis, the culture emphasizes innovation, collaboration, scientific rigor, and a strong patient-first orientation, particularly critical in the pioneering field of gene therapy.
HQ Significance:
Historically the headquarters of AveXis, this location was instrumental in the development of Zolgensma® and remains a center of excellence for Novartis in the gene therapy field, driving innovation and manufacturing expertise.
Values Reflected in HQ: The site embodies Novartis's commitment to pioneering science, transformative therapies, and addressing unmet medical needs for patients with rare genetic diseases.
Location:
As part of Novartis, Novartis Gene Therapies's reach is global. Novartis has operations in approximately 140 countries worldwide. The gene therapy products, like Zolgensma, are approved in numerous countries across North America, Europe, Asia, and Latin America. The global presence supports clinical trials, regulatory affairs, manufacturing, and commercialization of gene therapies, aiming to bring these transformative treatments to patients globally. Manufacturing and R&D sites are strategically located in the US and Europe.
Street Address:
2275 Half Day Road, Suite 200
City:
Bannockburn
State/Province:
Illinois
Country:
USA
Novartis Gene Therapies's Global Presence
Durham, North Carolina, USA
Address: 1 T.W. Alexander Drive, Durham, NC 27703, USA
Serves as a primary gene therapy production and supply chain hub for the United States and global markets, with advanced capabilities in viral vector manufacturing.
Longmont, Colorado, USA
Address: 4000 Nelson Rd, Longmont, CO 80503, USA
Contributes to the global supply of gene therapies, focusing on scalable and efficient manufacturing processes.
San Diego, California, USA
Address: 10675 John Jay Hopkins Dr, San Diego, CA 92121, USA (Novartis Institutes for BioMedical Research - NIBR)
Focuses on cutting-edge biomedical research and discovery, feeding into Novartis's global drug development pipeline, including innovative genetic medicines.
Libertyville, Illinois, USA
Address: 1950 USG Drive, Libertyville, IL 60048, USA
Supports the overall manufacturing capacity for Novartis's gene therapy portfolio.
Buying Intent Signals for Novartis Gene Therapies
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Novartis Gene Therapies
As of April 2025, Novartis Gene Therapies' leadership includes:
Investors of Novartis Gene Therapies
Novartis Gene Therapies has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Novartis has been integrating its Gene Therapies unit into the broader organization, leading to some leadership transitions and role alignments within the parent company. Key appointments at the Novartis corporate level also significantly impact the strategy and development of gene therapies.
Departures
New Appointments:
Technology (Tech Stack) used by Novartis Gene Therapies
Discover the tools Novartis Gene Therapies uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Novartis Gene Therapies Email Formats and Examples
Novartis, including its Gene Therapies division, commonly uses a standard corporate email format. The most prevalent format is combining the employee's first name and last name, separated by a dot.
firstname.lastname@novartis.com
Format
john.doe@novartis.com
Example
90%
Success rate
News and media
Novartis Press Release • March 25, 2024
Novartis Gene Therapies News: Novartis presents new data for Zolgensma showing age-appropriate development in children with SMA treated presymptomatically or symptomatically and long-term durability in older children now up to five years post-treatment
Novartis announced new data presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting reinforcing the transformative and sustained benefit of Zolgensma (onasemnogene abeparvovec), its gene therapy for spinal muscular atrophy (SMA). The data highlighted age-appropriate development in children treated presymptomatically and long-term durability....more
Endpoints News • October 5, 2023
Novartis Gene Therapies News: Novartis folds gene therapy unit into R&D, reshuffles commercial leaders
Novartis announced it is integrating its standalone gene therapy unit into its broader research and development organization. This move aims to streamline operations and accelerate the development of new gene therapies by leveraging the full scale and expertise of Novartis's global R&D engine....more
Novartis Press Release • July 18, 2023
Novartis Gene Therapies News: Novartis highlights strong performance of Zolgensma in Q2 2023 earnings
In its Q2 2023 financial results, Novartis reported continued strong performance for Zolgensma, with sales of USD 319 million. The company emphasized its commitment to expanding access to the gene therapy globally and advancing its pipeline of gene therapy candidates....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Novartis Gene Therapies, are just a search away.